A Randomized, Open-label Phase 3 Study of Combination Amivantamab and CarboplatinPemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Authors
Category Primary study
Registry of TrialsClinical Trials Information System
Year 2025
This article has no abstract
Epistemonikos ID: ae05148c6105f689f451e22c82500b218fa0cb18
First added on: Jan 16, 2026